CLAIMS

1. A method of improving female sexual function and/or treating a female sexual disorder, the method comprising applying a topical composition to a female subject's genital (arousal) area(s), wherein said topical composition formulated with liposomes that comprise cannabidiol (CBD) and, optionally, one or more additional cannabinoids, and wherein the CBD-containing composition is applied to mucosal surface in the amount and for a period of time prior to a sexual activity such that sexual function of the subject is enhanced and/or the disorder is ameliorated during the sexual activity.

2. The method of claim 1, wherein the genital area includes genitalia with absorptive mucosa, comprising one or more of: the introitus, the vulva, the labia minora, the clitoris and the vaginal vault.

3. The method of claim 1, wherein the enhancement of the sexual function and/or amelioration of the disorder is exhibited by one or both of the following parameters:

i. vaginal and clitoral smooth muscle relaxation; and

ii. increased vaginal and clitoral blood flow.

4. The method of claim 1, wherein the enhancement of the sexual function and/or amelioration of the disorder is exhibited by one or more of the following subjectively self-reported outcomes including:

i. “increased lubrication/wetness during sexual activity”;

ii. “reaching orgasm more often”;

iii. “greater ease or achieving orgasm”;

iv. “being more satisfied”;

v. “higher level of sexual desire”; and

vi. “reduction in pain during sexual activity”.

5. The method of claim 1, wherein the subject is premenopausal.

6. The method of claim 3 or 4, wherein the outcomes are reported by post-menopausal women are similar to those reported by premenopausal women with respect to one or more of the following parameters:

i. improved arousal;

ii. improved lubrication; and

iii. improved ease of achieving orgasm.

7. The method of claim 1, wherein the total amount of CBD applied is from 5 mg to 1,000 mg of CBD, preferably 10-100 mg of CBD, more preferably, 20-40 mg of CBD.

8. The method of claim 1, wherein the CBD-containing composition is applied at 5-30 mins prior to the sexual activity.

9. The method of claim 1, where the additional cannabinoid(s) is/are selected from the group consisting of Δ^9-THC, Δ^8-THC, CBD, and CBN.

10. The method of any of the preceding claims, where is CBD is hemp-derived and/or contain less 0.3% THC by weight.

11. The method of claim 1, wherein the CBD-containing composition is provided in a single-use container.

12. The method of claim 1, wherein the CBD-containing composition further comprises preservative(s) and is provided in a multi-use container.

13. The method of claim 1, wherein the CBD-containing composition is compatible with latex and polyisoprene condoms.

14. The method of claim 1, wherein the CBD-containing composition is provided by means of a condom pre-coated with the composition.

15. The method of claim 1, wherein the concentration of CBD in the composition is from 1 mg/ml to 40 mg/ml, preferably, 5 mg/ml to 20 mg/ml, more preferably, 10 mg/ml.

16. The method of claim 1, wherein CBD-containing composition comprises liposomes that comprise HSPC, ascorbic acid, sodium ascorbate, propylene glycol, polyacrylate crosspolymer-6, and water or aqueous buffer, and wherein the liposomes are provided in a homogeneous suspension.

17. The method of claim 1, wherein the composition is applied 1-60 min prior to sexual activity, preferably, 5-40 min, more preferably 15-20 min.

18. The method of claim 1, wherein the subject is afflicted with a disorder selected from (1) Sexual Interest/Arousal Disorder (SIAD) and (2) Female Orgasmic Disorder.

19. The method of claim 18, wherein the subject, upon having been treated with the CBD-containing composition for 3-6 months, reports arousal and or orgasmic improvements as measured by FSFI.

20. The method of claim 18, wherein the improvement in sexual interest/arousal domain is by 1.5-2 points, and by 1.5-2 points in the orgasm domain of the FSFI.

21. The method of claim 1, wherein the off-set time following the application of the CBD-containing composition is 0.5-5 hrs, preferably, 1-3 hrs, more preferably 1-2 hrs.

22. The method of claim 1, wherein CBD-containing composition further comprises a phosphodiesterase type 5 inhibitor.

23. The method of claim 1, wherein the inhibitor is chosen from sildenafil, tadalafil, vardenafil, and udenafil.

24. The method of claim 1, wherein CBD-containing composition further comprises another direct smooth muscle relaxant.

25. The method of claim 24, wherein the relaxant is chosen from prostaglandin E1, papaverine, and minoxidil.

26. The method of claim 1, wherein CBD-containing composition further comprises an alpha-blocker.

27. The method of claim 1, wherein the alpha-blocker is phentolamine.

28. The method of claim 1, wherein CBD-containing composition further comprises flibanserin thereby augmenting sexual desire.

29. The method of claim 1, wherein CBD-containing composition further comprises bremelanotide thereby augmenting sexual desire.